# Combination Therapy With Nivolumab and PD-L1/IDO Peptide Vaccine to Patients With Metastatic Melanoma

> **NCT03047928** · PHASE1,PHASE2 · COMPLETED · sponsor: **Inge Marie Svane** · enrollment: 48 (actual)

## Conditions studied

- Metastatic Melanoma

## Interventions

- **DRUG:** Nivolumab
- **BIOLOGICAL:** PD-L1/IDO peptide vaccine

## Key facts

- **NCT ID:** NCT03047928
- **Lead sponsor:** Inge Marie Svane
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-02-22
- **Primary completion:** 2022-12-31
- **Final completion:** 2022-12-31
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2025-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03047928

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03047928, "Combination Therapy With Nivolumab and PD-L1/IDO Peptide Vaccine to Patients With Metastatic Melanoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03047928. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*